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Purpose: To describe patterns of prescribed drug use over time among primiparous women 
in Denmark.
Methods: Through the Danish Medical Birth Registry, we identified all primiparous women 
  giving live birth or stillbirth at $ 22 gestational weeks in northern Denmark, from 1999 to 2009. 
From the Aarhus University Prescription Database we obtained information on the women’s 
prescriptions for reimbursed drugs filled from 30 days before conception until delivery.
Results: Among 85,710 primiparous women, 47,982 (56.0%) redeemed at least one prescription 
from 30 days before conception until delivery. Women aged 35 years and older had the highest 
overall prevalence of prescription drug use (61.1%). Age-standardized prevalence of drug use 
was 54.7% in 1999 and 61.2% in 2009, prevalence ratio (PR) of 1.13 (95% confidence interval 
1.10; 1.16), adjusted for age and smoking.
Conclusion: Over the 11-year period from 1999 to 2009, we found a modest increase in overall 
use of drugs by primiparous women in Denmark. This increase was not, however, explained 
by an increasing proportion of older first-time mothers. We noted changes in patterns of use of 
anti-infective drugs and antidepressants.
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Introduction
Reported prevalence of drug use during pregnancy in Western countries ranges from 
44% to 99%, and many pregnant women use several different drugs.1–7 Because preg-
nant women are typically excluded from randomized studies of drugs, evidence about 
drug utilization and safety in pregnant women comes primarily from surveillance.8,9
Despite lack of data on safety, drug therapy during pregnancy is sometimes required 
to treat maternal conditions.10 Women in developed countries are delaying childbear-
ing into later reproductive years:11 in Denmark, the prevalence of first-time mothers 
older than 30 years has increased from 29% in 1997 to 41% in 2007.12 Temporal 
changes in demographic, social, or clinical characteristics of pregnant women as 
well as modifications in treatment guidelines may affect patterns of drug utilization 
in pregnancy.10,13
Previous studies have mainly reported period prevalence of drug use among preg-
nant women, and have examined use according to trimester of pregnancy.1–7 Little data 
exist on temporal changes in drug use during pregnancy.10,14 In this population-based 
study, we examined changes in patterns of prescribed drug use from 1999 to 2009 
among Danish primiparous women.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Methods
study population
In the Danish Medical Birth Registry, we identified all 
primiparous women (ie, women delivering their first live- or 
stillborn child at $22 weeks’ gestation)15 from 1 January 
1999 to 31 December 2009 in the Central and the North 
Denmark Regions, which together comprise about 33% of 
the total Danish population (1.8 million people). The Medical 
Birth Registry has recorded all births in Denmark since 1973 
and contains data on characteristics of the mother (including 
age, residence, parity, and self-reported smoking status) and 
the newborn (including vital status at birth, sex, gestational 
age, and birth weight).16 The information on gestational age 
is based on ultrasound and is recorded in full completed 
weeks (through 1996) and in fractional weeks (based on days) 
thereafter.17 We calculated the conception date as birth date 
minus gestational age in days plus 14 days.
Identification of prescribed drugs
We obtained information on drug use in pregnancy using 
the Aarhus University Prescription Database, which tracks 
prescriptions for reimbursed drugs redeemed at the regions’ 
outpatient pharmacies.18 The pharmacies use electronic 
accounting systems to secure reimbursement from the 
National Health Service. Denmark’s tax-supported health 
care system partially refunds the costs of most prescribed 
drugs.19 To secure full prescription records for each pregnancy 
in the study population, we restricted our study to women 
who were residents of the two regions from 30 days before 
conception until delivery and who were therefore assumed to 
have redeemed their   prescriptions in the regions’ outpatient 
pharmacies.
We defined drug use as a record of at least one prescription 
dispensation recorded in the Aarhus University Prescription 
Database from 30 days before conception until delivery. For 
all prescriptions, we noted the woman’s personal   identifier, 
date of reimbursement, and type of medication, coded using 
the Anatomical Therapeutic Chemical (ATC)   classification. 
The Aarhus University Prescription Database does not track 
in-hospital medicinal treatment. Nonreimbursed drugs 
  (over-the-counter [OTC] preparations, prescription sedatives, 
hypnotics, or oral contraceptives) are not recorded unless 
they are approved for reimbursement, eg, to treat a chronic 
condition.18
Data linkage
Data were linked using the unique 10-digit personal identi-
fier (“CPR number”), assigned to all Danish residents at 
birth by the Civil Registration System since 1968.20 The 
CPR number, which encodes date of birth and sex, is used 
in all public records. Maternal CPR number is a variable 
on the newborn’s Medical Birth Registry entry, enabling 
unambiguous linkage to the maternal prescription record. 
Furthermore, the Civil Registration System contains a vari-
able encoding residence.
statistical analyses
We computed prevalence of drug use among primiparous 
women according to maternal age at delivery (,25 years, 
25–29 years, 30–34 years, and $35 years), smoking during 
pregnancy (yes/no), and categories corresponding to the 
major anatomical ATC groups.21 We further analyzed six 
major anatomical ATC groups with prevalence of use in 
pregnancy exceeding 4%. These groups, listed in the order 
of decreasing prevalence of use, were: anti-infective drugs 
for systemic use (ATC group J), gynecological drugs (ATC 
group G), dermatological drugs (ATC group D), drugs for 
respiratory diseases (ATC group R), drugs for alimentary 
tract and metabolism (ATC group A), and neurological 
drugs (ATC group N). In 1998, clinical guidelines were 
introduced in Denmark for treatment of asymptomatic 
urinary tract infections in pregnancy.22,23 For anti-infective 
drugs, we therefore specifically examined prevalence 
of drug use indicated for urinary tract infections (UTIs) 
(sulfamethizole (J01EB02), pivmecillinam (J01CA08), and 
nitrofurantoin (J01XE01)), while examining use of penicillin 
  (phenoxymethylpenicillin (J01CE02), pivampicillin 
(J01CA02), and amoxicillin (J01CA04)) for comparison. 
After observing an increasing trend in use of neurological 
drugs throughout the study period, we did a post-hoc analysis 
to examine change over time in prevalence of drug use in 
specific subgroups: antidepressants (N06A), anti-epileptics 
(N03), and opioids (N02A).
We computed age-standardized prevalence of drug use 
in each calendar year (1999–2009), with age distribution in 
year 1999 as the standard. Further, we estimated age- and 
smoking-adjusted prevalence ratios (PRs) for drug use with 
corresponding 95% confidence intervals (CIs), using 1999 
as the referent year. Furthermore, we tested for presence of 
a trend across years using the Chi-square test for trend.
We examined patterns of drug use over time within four 
gestational periods: immediate pre-conception (1–30 days 
before estimated conception), first trimester (gestational 
week 1–12), second trimester (gestational week 13–28), 
and third trimester (gestational week 29 to delivery). 
We compared pre-conception and trimester-specific Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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prevalence of drug use in 1999–2000 (the first two years 
of observation) with that in 2008–2009 (the last two years 
of observation). Using years 1999–2000 as the reference, 
we estimated gestational-period specific prevalence ratios 
for drug use, adjusted for age at delivery and smoking in 
pregnancy.
All analyses were performed using Stata software 10.0 
(College Station, TX). The study was approved by the Danish 
Data Protection Agency (journal number: 2003-41-3103).
Results
During the study period, we identified 85,710 primiparous 
women, delivering 88,003 live- or stillborn children. Mean 
age at delivery was 28 years (range 13–52 years); the 
proportion of first-time mothers aged 30 years and older 
increased from 29.0% in 1999 to 35.8% in 2009. Compared 
with all primiparous women, those with prescription drug 
use were more likely to be smokers, to have multiple births, 
and to be older. Prevalence of preterm birth and low birth 
weight differed slightly among groups (Table 1).
Overall, 47,982 (56.0%) of primiparous women redeemed 
at least one prescription for a reimbursed drug from 30 days 
before conception until delivery. Women who redeemed 
prescriptions, redeemed, on average, 3.2 prescriptions (2.3% 
of these redeemed .10 prescriptions). Women who used 
anti-infective drugs redeemed on average 1.6 prescriptions 
(lowest prescription rate per woman), whereas women who 
used neurological drugs on average redeemed 4.0 prescrip-
tions (highest prescription rate per woman).
The age-standardized prevalence of drug use increased 
from 54.7% in 1999 to 61.2% in 2009, PR 1.13 (95% con-
fidence intervals [CI]: 1.10; 1.16); the prevalence decreased 
slightly in the first two years of observation.The overall 
prevalence of drug use was 58.5% among women younger 
Table  1  Characteristics  of  primiparous  women  in  northern 
Denmark 1999–2009
All primiparous 
women 
(n = 85,710)
Primiparous women 
who redeemed at least 
one prescription during 
pregnancy 
(n = 47,982)
Age at delivery, years
 , 25 18,170 (21.2) 10,637 (22.2)
  25–29 39,221 (45.8) 20,824 (43.4)
  30–34 21,540 (25.1) 12,382 (25.8)
  $35 6779 (7.9) 4139 (8.6)
smoking during 
pregnancya
15,046 (17.6) 9014 (18.8)
single births  83,405 (97.3) 46,348 (96.6)
Twin births  2256 (2.6) 1593 (3.3)
Triplet births 49 (0.1) 41 (0.1)
Low birth weightb 
(,2500 g)
3975 (4.8)c 2309 (5.0)c
Preterm birth 
(,37 weeks)
5550 (6.7)c 3217 (6.9)c
stillbirth 
($22 weeks)
362 (0.4)c 221 (0.5)c
Notes: a1826 missing values (2.1%); b494 missing values (0.6%); csingleton pregnancies   
only.
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than 25 years, 53.1% among women between 25 and 29 years, 
57.5% among women aged 30–34 years, and 61.1% among 
women aged 35 years and older. Throughout the study period, 
women aged 25–29 years had a lower prevalence of drug use 
than women in other age groups (Figure 1). Drug use over 
time in each age group was tested for trend (P , 0.001 for 
linear trend in all age groups).
Table 2 shows prevalence of drug use stratified by calendar 
year and ATC group and PRs of drug use adjusted for age and 
smoking. Anti-infective drugs were the most prevalent drugs 
used the by the primiparous mothers as measured by one or 
more dispensed prescriptions. The age-standardized preva-
lence of use of anti-infective drugs increased from 25.5% in 
1999 to 36.3% in 2009, PR 1.44 (95% CI: 1.38; 1.51). Women 
younger than 25 years had a higher prevalence of anti-infective 
drug use (37.3%) compared with women in all other age 
groups: 28.1% of women between 25 and 29 years; 28.3% 
of women aged 30–34; and 27.8% of women aged 35 years 
and older. There were 14,469 (16.9%) women redeeming one 
or more prescriptions for UTI antibiotic drugs and 11,761 
(13.7%) women redeeming one or more prescriptions for 
penicillin. The prevalence of UTI-specific drug use more 
than doubled (10.9% in 1999; 22.9% in 2009, PR 2.15 [95% 
CI: 1.99; 2.31]) and the increasing prevalence was observed in 
all age groups (data not shown). We also observed an increase 
over time in the prevalence of penicillin use (13.3% in 1999; 
14.1% in 2009, PR 1.10 (95% CI: 1.02; 1.19)).
The age-standardized prevalence of neurological drug 
use increased nearly three-fold (2.3% in 1999; 6.5% in 
2009, PR 2.97 [95% CI: 2.52; 3.52]) (Table 2). At any time 
  during pregnancy, 1872 (2.2%) women used antidepressants, 
582 (0.7%) used opioids, and 451 (0.5%) used anti-epileptics. 
Prevalence of antidepressant use increased nearly six-fold 
(0.8% in 1999; 4.1% in 2009, PR 5.95 [95% CI: 4.51; 7.85]).
Prevalences of gestational-period specific drug use in 
1999–2000 and 2008–2009 are shown in Figure 2. Over time, 
prevalence of immediate pre-conception and trimester-specific 
use of anti-infective drugs increased. Prevalence of trimester-
specific use of neurological drugs also changed over time. For 
example, first-trimester use increased more that three-fold from 
1.4% in 1999–2000 to 4.1% in 2008–2009, PR 3.19 (95% 
CI: 2.73;3.74); second trimester use increased more that four-
fold from 0.8% in 1999 to 3.4% in 2009, PR 4.30 (95% CI: 
3.54;5.22); and third trimester use increased from 0.7% in 1999 
to 2.3% in 2009, PR 3.54 (95% CI: 2.85;4.40). Prevalence of 
immediate pre-conception use of gynecological drugs more than 
doubled from 1999–2000 to 2008–2009 (3.9% in 1999–2000; 
9.3% in 2008–2009, PR 2.18 (95% CI: 2.00; 2.39), whereas 
third-trimester use almost halved from 3.2% in 1999–2000 to 
1.8% in 2008–2009, PR 0.57 (95% CI: 0.49; 0.66).
Discussion
Use of prescribed reimbursed drugs increased modestly 
(6.5% in absolute terms) from 1999 to 2009 in this population 
of almost 86,000 primiparous women. From 2001 to 2005, 
the Danish Institute of Public Health reported a 24% 
increase of prescribed drug use measured in defined daily 
doses (DDDs) among the general Danish population.24 The 
Figure 2 Prevalence (per 1000 women) of immediate pre-conception and trimester-specific drug use among primiparous women for the most commonly prescribed ATC 
groupsa 1999–2000 and 2008–2009.
Notes: aATC group A: drugs for alimentary tract and metabolism; ATC group D: dermatological drugs; ATC group g: gynecological drugs; ATC group J: anti-infective drugs 
for systemic use; ATC group n: neurological drugs; and ATC group r: drugs for the respiratory system.
0
20
40
60
80
100
120
140
160
180
ADGJ NRADGJ NRADGJ NRADGJ NR
≤30 days before
pregnancy
First trimester  Second trimester Third trimester
P
r
e
v
a
l
e
n
c
e
 
o
f
 
p
r
e
s
c
r
i
b
e
d
 
d
r
u
g
u
s
e
 
/
 
1
,
0
0
0
 
w
o
m
e
n
1999 + 2000
2008 + 2009Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
154
Bjørn et al
observed modest increase in drug use among women giving 
first birth could thus be a reflection of this general population 
trend. The overall prevalence of drug use increased with 
age; however, increasing age of primiparous women did 
not explain the overall increase in prevalence of drug use 
over time. Anti-infective drugs were used with the highest 
prevalence as measured by one or more prescription dispensa-
tion. Prevalence of antidepressant use increased substantially 
over the observation period, but the absolute prevalence 
remained low.
Prevalence of drug use in pregnancy was on the same 
order of magnitude in other Nordic countries as in the 
present study. In Sweden (2007), the prevalence of drug 
use was 58% among pregnant women;7 in 2004–2006, 
in Norway, prevalence of drug use during pregnancy was 
57% at any time during trimester 1–3 among first single-
ton pregnancies,3 while in Finland, the prevalence of use 
was 46% in 1999.5 Comparability of findings is expected 
as Nordic countries have similar health care and record-
keeping practices.25
Non-Nordic countries have reported higher prevalence 
of drug use during pregnancy.1,2,4 According to records from 
the French Health Insurance Service, 99% of women in 
  Southwest France receive prescribed drugs during   pregnancy.4 
In the United States, 82% of pregnant women used prescribed 
drugs, based on data collected from the Health Maintenance 
Organizations (HMO) in 1996–2000.1 Both in France and in 
the United States, the reported drug use includes certain OTC 
medications, such as iron, folic acid, and pregnancy vitamins. 
In particular, in the United States (in contrast to Denmark), 
pregnant women receive prescriptions for pregnancy vitamins 
in order to enable reimbursement, and therefore leading to a 
dispensation record. Thus, patterns of drug utilization during 
pregnancy can be expected to vary according to prescribing, 
reimbursement, and record-keeping practices, as well as 
socioeconomic differences.1–5
Drug utilization patterns varied by age and by type of 
drug. Our finding that women aged 35 years or older had a 
slightly higher prevalence of overall drug use than women 
in younger age groups is similar to findings in a recent Irish 
study including 61,252 women giving birth in Dublin from 
2000 to 2007.26 Young age, however, has been associated 
with a higher use of antibiotics, as observed in a German 
study of about 41,000 observations based on insurance 
claims. This observation was confirmed in our study. The 
German researchers attributed higher use of antibiotics by 
younger pregnant women to higher rates of infections in 
this age group.27 Screening for bacteriuria as part of routine 
examination of pregnant women was introduced in Denmark 
in 1998,22,23 probably partially explaining our observation of 
increased use of UTI-specific drugs among women giving 
first birth throughout the study period. In 2001, some drugs 
used in treatment of gynecological infections were re-coded 
from gynecological drugs to the anti-infective drugs for 
systemic use,28 which may account for some of the decrease 
seen for gynecological drugs and some of the increase seen 
for anti-infective drug use observed in our study. An increased 
prevalence of prescribed antidepressant drug use seen in this 
study was also reported in the United States.29,30 Exposure 
to antidepressants (selective serotonin reuptake inhibitors 
[SSRIs] in particular) in early pregnancy has been associated 
with an increased risk of adverse neonatal effects.14,31,32 That, 
together with our findings that use of neurological drugs 
increased in early pregnancy during our study period, may 
call for further attention.
It is important to acknowledge different strengths and 
weaknesses of our study when interpreting our results. 
Our large and well defined study population contained data 
from a uniform health care system with complete coverage 
and universal access. We used data from a system of auto-
matic reimbursement and routine electronic record-keeping. 
This enabled us to avoid recall bias, and estimate drug utiliza-
tion systematically.33
We focused on trends in use of broad groups of pre-
scription drugs according to major anatomical ATC-groups 
in order to give the general descriptive picture of drug 
  utilization patterns among primiparous women. We did not 
aim to specifically address utilization of known or potential 
teratogens. Reports that almost 20% of Canadian women 
(study population = 18,575)34 and 10% of US women 
(study population = 152,531)1 used prescription drugs with 
potential or clear fetal risk during pregnancy call for further 
attention. However, the teratogenic potential of many drugs 
is unknown35 and deserves special investigation.
The Aarhus University Prescription Database lacks 
information on dispensation of OTC drugs, in-hospital 
treatment, or sales of nonreimbursed prescribed drugs.18 
Therefore the overall prevalence of prescription drug use 
among women giving first birth is underestimated and cau-
tion about conclusions regarding the observed change of 
drug utilization patterns in specific ATC-groups,eg neuro-
logical drugs, need to be considered. Furthermore, because 
we used information on redeemed prescriptions, we had 
no data about the true drug intake, potentially leading to 
overestimation of the actual use of the purchased drugs.36 
Although we examined the effect on utilization of maternal Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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age and self-reported smoking, we had no data on other 
factors, such as social status and years of education, which 
could also explain some of the change in use. Further, we 
restricted the study population to primiparous women to 
maximally remove the effects of age from evaluating the 
trends of drug use.
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